Combined #ICI and #VEGFI treatment regimens & trials are on the rise📈Are #CV eligibility criteria and #AE reporting keeping up? JACC Journals #JACCCardioOnc

🧐tinyurl.com/yjwby5uf

Day 2 of #GTS 2024 starts in 90 minutes. All who register can view the best summary of 2023-24 trials for 12 months FOR FREE. Register at events.hubilo.com/global-trials-…. Day 2 is intervention, structural heart disease, EP, AF and hot trial updates.

Honored, humbled and very excited to be selected as candidate for position of president-elect for the #HFA board elections!
To all members, please don’t forget to vote for these fantastic people!
escardio.org/Sub-specialty-…
Here are my top six priorities....together we can make it…

#GTS2024 Currently Dr Javed Butler is speaking about Obesity, MI and Lipids and specifically 'EMPACT-MI and Beyond'. Next up Dr Steven E Nissen will be presenting on CLEAR outcomes.
Register now to attend
events.hubilo.com/global-trials-…

Day 1 of #globaltrialssummit starts in 6 hours.... All the major leaders present live. Register at events.hubilo.com/global-trials-… #GTS2024 . Those registered can view all for 12 months.

In REVIVED, PCI did not prolong life in patients with ischemic LV dysfunction. But what about symptoms? Our detailed analysis of health status and quality of life out this week in JACC: Heart Failure. jacc.org/doi/10.1016/j.…

Dr Simon Beggs presents novel characterisation of mechanisms of death in #heartfailure at #ACC24

Look forward to hearing more from #RHYTHMHF

#RoyGardner Mark Petrie University of Glasgow Heart Failure Research Group Ninian Lang

🔥 THIS JUST IN 🔥

⁦Javed Butler⁩ ⁦Mikhail Kosiborod⁩

Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials - The Lancet thelancet.com/journals/lance…

Well done Mikhail Kosiborod Mark Petrie for conducting and leading the #STEP_HFpEF_DM trial NEJM Showing improved outcomes on #6MWT and #KCCQ British Society for Heart Failure #theFword Pumping Marvellous Foundation #CardioTwitter

Fantastic work Holly

Breaking🔥 STEP-HFpEF-DM 🔥

Semaglutide (vs placebo) leads to more weight loss, improved health status (KCCQ-CSS), increased walking distance, improved glycemic control, reduced inflammation (CRP), reduced natriuretic peptides, reduced HF hospitalizations, with favorable safety…

Among patients with obesity-related heart failure with preserved ejection fraction & type 2 diabetes, semaglutide produced greater reductions in symptoms, physical limitations & body weight than placebo at 1 year. Full STEP-HFpEF DM trial results: nej.md/3TPKpUC

#ACC24

The benefits of semaglutide #T2D in HFpEF do not appear to be strictly related to #weightloss and remain evident on top of SGLT2i (32.8%) and mineralocorticoid receptor antagonists (32.5%) nejm.org/doi/full/10.10…

Decreasing the Risk of #HeartFailure in a Changing Post–Myocardial Infarction Environment

This editorial discusses new insights from #EMPACT -MI trial

nejm.org/doi/full/10.10…

NEJM #ACC24 Javed Butler Steve Greene Muthu Vaduganathan

Welcome to the @BCIS4trial X page. This study is funded by the National Institute of Health Research (NIHR) [HTA (NIHR155123]. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care

Mon 8th April (Atlanta) Matt Ryan

0915 (Rm B213) Does LGE predict segmental recovery in severe LVSD? REVIVED analysis

1015 (theater 3) Quality of Life after PCI in severe LVSD: a #WinRatio analysis REVIVED. @JACCjournals
Clinical Trials Unit - Global Health Trials Group Mark Petrie John Spertus

Only three weeks left until #globaltrialssummit2024 . Have you registered your place yet for this 2-day online summit? Registration is free for all #healthcare and #medical professionals. events.hubilo.com/global-trials-…

The Lancet podcast is out! Easily digestible bite-size answers to commonly asked questions about our paper HFpEF - everything the clinician needs to know. Check out myself and co-author Frans Rutten on thelancet.com/lancet/audio